View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 27, 2021

Boehringer to start Phase III study of alteplase to treat Covid-19

The company will start the Phase III TRISTARDS clinical trial of alteplase in the context of its Covid-19 therapy research.

Boehringer Ingelheim has plans to commence the Phase III part of its Phase II/III TRISTARDS clinical trial of alteplase to treat Covid-19 patients suffering from acute respiratory distress syndrome (ARDS).

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The announcement comes after the drug showed favourable safety and efficacy profile in an interim analysis of the trial, in which the exploratory open-label Phase IIb part with 62 participants is complete.

During the Phase IIb part, the efficacy and safety of two intravenous alteplase dosing regimens administered over up to five days along with the standard of care (SOC) were compared to SOC alone.

Based on the Phase II data, the company decided to direct its Covid-19 therapy research on developing an alteplase.

The plan is to begin the Phase III part of TRISTARDS in the fourth quarter of this year to validate and additionally evaluate the drug’s effects in Covid-19-related ARDS patients.

Boehringer also intends to start preparations for potential applications to seek regulatory approval.

Boehringer Ingelheim board of managing directors member Michel Pairet said: “If the Phase III part of TRISTARDS confirms the favourable interim results from the Phase II, alteplase could have the potential to become a new therapy option for the most severely affected Covid-19 patients.”

Alteplase is said to be the first licensed treatment to dissolve blood clots for acute ischemic stroke treatment.

The drug can also be used to treat acute myocardial infarction, acute massive pulmonary embolism and catheter clearance associated with thrombotic occlusion.

Boehringer launched the TRISTARDS trial after investigator-initiated studies indicated the drug’s potential for treating Covid-19 ARDS in patients who are severely ill.

Apart from focusing on alteplase for Covid-19, the company has decided to discontinue the development programme of BI 767551 SARS-CoV-2 neutralising antibody.

The decision is based on evolving SARS-CoV-2 landscape, including the success of vaccines, existing neutralising antibody programmes and emerging variants.

The programme of Boehringer’s neutralising antibody included trials analysing the delivery through inhalation, which the company expects to be a feasible route of administration for quick activity onset.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena